The FDA authorizes the COVID booster shots for children as young as 5; babies born during the pandemic may experience delayed communication skills compared with babies born prior; regulatory burden has increased for 89% of medical practices.
The Moderna bivalent vaccine for children aged 6 and older and Pfizer’s updated shot for children aged 5 and older were both approved by the FDA on Wednesday. The CDC also agreed, clearing the way to begin administration; both vaccines are aimed at the Omicron BA.4 and BA.5 subvariants. According to Reuters, Pfizer will start shipments immediately.
According to NBC News, a study found that babies who were born during the pandemic have had a longer uptake on developmental milestones when compared with babies who born before the pandemic. The study that was conducted by researchers at the Royal College of Surgeons in Dublin, Ireland, found that infants from Ireland who were born from March to May of 2020 had a harder time communicating when they were aged 1 year compared with children born between 2008 and 2011. About 89% of infants born between 2008 and 2011 could articulate full words like “bowl” and “cup” at 12 months compared with 77% of infants born during the pandemic.
Most medical practices in the United States have faced an increase in regulatory burden over the previous 12 months, according to Becker’s Hospital Review. A report published by the Medical Group Management Association found that 89% of the 500 medical group practices that responded saw an increase in overall regulatory burden in the past year. A total of 97% of respondents also said that reducing regulatory burden on their practice would allow for reallocation of resources to better serve patient care. This finding mostly concerned smaller practices, as 64% of respondents reported working in practices with less than 20 physicians.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More